AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04507269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection
Study NCT01225107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry Extract
Description: 500mg TID
Study NCT01225107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inert Placebo Capsule
Description: Inert substance, 3 times per day in capsule form
Study NCT02035475 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intuitive Vessel Sealer
Description: Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
Study NCT00355654 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DT5aP-IPV-Hib 5-component Pertussis vaccine
Description: 0.5 mL, IM
Study NCT00355654 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DT3aP-HBs-IPV
Description: 0.5 mL, IM
Study NCT04307914 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: The current standard of care for patients with uncomplicated painful bone metastases is palliative locoregional external beam radiotherapy, often in combination with systemic therapy and analgesics.
Study NCT04307914 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiotherapy
Description: The current standard of care for patients with uncomplicated painful bone metastases is palliative locoregional external beam radiotherapy, often in combination with systemic therapy and analgesics.
Study NCT04307914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR-HIFU
Description: MR-HIFU is a non-invasive treatment modality that delivers acoustic energy to heat tissue to ablative temperatures of more than 60°C. The combination of focused ultrasound with magnetic resonance imaging (MRI) enables physicians to perform localized tumor tissue ablation, with real-time temperature monitoring using magnetic resonance (MR) thermometry.
Study NCT04595344 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listening to Pure Binaural Beats
Description: The patients in DCG ((binaural beat group) ) and USRG (binaural beat group) listened to binaural beats.The binaural beats were produced using a software program (Audacity®, version win. 2.3.2, 2019 Audacity Team) at frequency of 10 Hz (a tone of 200 Hz in the right ear and a tone of 210 Hz in the left ear). The binaural beats that the patients in DCG-1 and USRG-1 listened to were pure frequencies, with no background music or waves.
Study NCT04595344 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listening to classical music
Description: The patients in DCG (classical music group) and USRG (classical music group) listened to classical music.The classical music that those in DCG-2 and USRG-2 listened to was Mozart's 40th Symphony.
Study NCT04595344 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No audio only headphone
Description: The patients in DCG (placebo group) and USRG (placebo group) sat in a quiet room with headphones on but no audio playing
Study NCT04507269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline given by subcutaneous injection
Study NCT02942875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mirror therapy
Description: During MT, subjects will sit in front of a table on which a mirror will be placed vertically in the space ipsilateral to the paretic upper limb with its reflective surface facing the unaffected upper limb. The subjects are required to look at the mirror to observe the reflective image of the unaffected arm from shoulder to the hand, while it is performing certain designated movements. At the same time, the affected arm will be required to follow the unaffected arm to practice the same movements.~The upper limbs movements during the 30-min MT session are open and close of grasp; wrist flexion and extension; forearm supination and pronation; elbow flexion and extension; shoulder flexion and extension. A total of 120 repetitions for each action will be practiced.
Study NCT02942875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control therapy
Description: Control group subjects undergo the same bilateral upper limbs exercise protocol without mirror
Study NCT02341105 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Pulmonary vein isolation by catheter ablation
Study NCT02341105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: antiarrhythmic therapy using Amiodarone
Study NCT00992329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciprofloxacin
Description: ciprofloxacin 200mg tablet (single dose)
Study NCT00992329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Description: ciprofloxacin 200mg tablet (single dose)
Study NCT02185846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DYNABAC 250 MG ENTERIC COATED TABLET
Study NCT02185846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIRITHROMYCIN 500 MG ENTERIC COATED TABLET
Study NCT04292392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preop ACB, followed by Intra-articular block during TKA surgery
Description: Preoperative ACB (adductor canal block), followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml
Study NCT04292392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preop ACB+IPACK block
Description: Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block
Study NCT04292392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preop ACB+IPACK block, followed by Intra-articular block during TKA surgery
Description: Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block, followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml
Study NCT02671773 — intervention group
Intervention type: DRUG
Intervention: Inhaled corticosteroid dose/type
Study NCT03833583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix Medical mini-CT tDCS stimulator
Description: Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks
Study NCT03833583 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Soterix Medical mini-CT tDCS stimulator
Description: Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks
Study NCT04229017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion
Description: Anterior Cervical Decompression and Fusion (ACDF) is a standard of care procedure that is performed using standard instruments and completed with an allograft interbody implant and anterior plate.
Study NCT00526604 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: work related rehabilitation
Description: The workplace intervention includes two steps:~Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.~Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks.
Study NCT02466373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml
Description: clonidine intravenous
Study NCT01624051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard dosing method arm: Cisplatin (chemotherapy) dosing based on body surface area
Description: Cisplatin dosing calculated at the rate of 75 mg/m2
Study NCT01624051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental dosing method arm: Cisplatin (chemotherapy) dosing based on individual lean body mass
Description: Cisplatin dosing calculated at the rate of 3.10 mg/kg lean body mass
Study NCT03300323 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: IV fluid challenge administration
Description: Administration of an intravenous fluid challenge to assess for fluid responsiveness
Study NCT04575844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 24 weeks of Liraglutide
Study NCT04575844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 24 weeks of Exercise training
Study NCT04575844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide + Exercise training
Description: 24 weeks of Liraglutide + Exercise training
Study NCT00973271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 290 mg DCCR
Description: 290 mg diazoxide choline
Study NCT04614077 — intervention group
Intervention type: OTHER
Intervention: ex vivo organ bath testing, preservation of vein sections without contact to patient
Description: 1 piece of vein is separated during surgical bypass procedure, then randomized and put ex vivo in two solutions: saline and specific solution, then tested in the organ bath
Study NCT00875147 — intervention group
Intervention type: DRUG
Intervention: bevacizumab
Description: Neoadjuvant chemotherapy with bevacizumab
Study NCT02439255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02439255 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02439255 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phytochemical
Description: Given black raspberry (BRB) nectar per oral (PO)
Study NCT02439255 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT02439255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening Questionnaire Administration
Description: Ancillary studies
Study NCT02439255 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Screening Questionnaire Administration
Description: Ancillary studies
Study NCT01671475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microEEG (Bio-Signal microEEG)
Description: At the core, the Bio-Signal microEEG, is an FDA approved miniature, battery-operated, multi-channel, and portable system that records wideband bioelectric signals. The microEEG combines the characteristics of low noise and small size, due to a number of fundamental design characteristics. It records, amplifies, and digitizes the signals at a point very close to the electrodes. This allows the length of the wires between electrodes and the recorder's amplifiers to be very short, keeping them out of the way. Short wires also reduce any inconvenience signal artifacts or other problems that may be associated with the length of the wires. The microEEG's dimensions are about 2x2x1.
Study NCT02158065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching program
Description: The coaching program consists of a (1) Step counter used as a coaching activity monitor to collect number of steps walked by the patients and (2) the Linkcare System, a mobile phone or tablet PC placed in the patient's home to collect data from the step counter. The system will set a daily activity goal for the patient based on achieved activity levels which will be measured by the step counter. Patients will also receive feedback, motivational and educational messages and direct calls from the coaching team at each institution.
Study NCT04210856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contemplative landscape exposure
Description: landscapes classified as contemplative (through a CLM psychometric measure) are expected to elicit different brainwave oscillations as compared to non-contemplative ones.
Study NCT00973271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 435 mg DCCR
Description: 435 mg diazoxide choline
Study NCT00973271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 135 mg fenofibric acid
Description: 135 mg fenofibric acid
Study NCT02999217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron isomaltoside
Description: Intravenous injection 1 g given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay.
Study NCT02999217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous injection given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay.
Study NCT00694811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Re-feeding duration
Description: 1 or 6 weeks of re-feeding after VLED-induced weight loss
Study NCT01452490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode Laser Treatment
Description: Laser treatment once every 6 weeks, for a total of 4 treatment sessions
Study NCT03486340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiologic assessment
Description: Aggressive ischemic risk factor management
Study NCT03949322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity Program
Description: The sessions in this program are similar to the adapted physical activity sessions already offered by sports therapy practitioners. This is an aerobic exercise session, with Nordic walking, and a combined session of muscle building and breathing exercises.
Study NCT00836810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timed Release Tablet Prednisone
Description: Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.
Study NCT00836810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.
Study NCT03229798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan Succinate Oral Tablet
Description: Sumatriptan succinate commercial Imitrex 100 mg tablet
Study NCT03229798 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transdermal delivery of sumatriptan succinate
Description: Sumatriptan succinate transdermal drug delivery system
Study NCT05548530 — intervention group
Intervention type: PROCEDURE
Intervention: Stereotactic intracranial hematoma puncture
Description: Check the CT scan of the patient's brain, find out the largest hematoma level of the patient, measure the coordinates of the puncture center, locate and mark the skull surface according to the coordinates obtained from the measurement, select the puncture point under the stereotaxic instrument, and mainly avoid important blood vessels , nerves and functional areas. Use an electric drill to drill the puncture needle into the center of the hematoma, and slowly aspirate the hematoma from the side hole until the suction stops when there is resistance. The residual hematoma in CT and the location of the drainage tube were determined, and the position of the puncture needle was adjusted for the situation of brain CT. After the operation, according to the re-examination of cranial CT, urokinase was injected into the hematoma cavity through the drainage tube to dissolve the residual hematoma, and the operation process strictly followed aseptic operation.
Study NCT05548530 — intervention group
Intervention type: PROCEDURE
Intervention: decompressive craniectomy
Description: Prior to the procedure, all patients obtained endotracheal intubation under general anesthesia following the informed consent provided by their family members. Upon identifying the hematoma's location through CT imaging, the surgeon made a linear or horseshoe-shaped incision on the scalp and subsequently opened the dura mater after creating a bone flap. The hematoma was punctured using a brain needle, allowing for effective decompression. The cerebral cortex was incised along the cerebral gyri, facilitating the separation of brain tissue to eliminate residual hematoma. Once hemostasis was ensured within the operative area, a silicone drainage tube was inserted, and the cranial bone flap was restored to its original position. In cases of severe brain edema or cerebral herniation, bone flap decompression was performed.
Study NCT05548530 — intervention group
Intervention type: PROCEDURE
Intervention: Neuroendoscopic
Description: The patient's preoperative CT and MR imaging data were fused with a neuronavigation system to avoid important functional areas and select the closest point of the hematoma to the cortex as the location point. Routine craniotomy was performed with a 2\*3 cm bone window, the puncture direction was repositioned by neuronavigation, the sheath was placed at the center of the hematoma, the core was removed, the endoscope was gradually aspirated, and the bleeding was stopped with electrocoagulation if there was considerable active bleeding. A drainage tube was placed, the bone flap was reset after surgery, and the scalp was sutured.
Study NCT01577043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racecadotril
Description: Racecadotril, 30 mg per sachet, dosage 1.5 mg./kg./day
Study NCT01577043 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cornstarch powder diluted in distilled water, dosage 2.5 ml per dose
Study NCT00895024 — intervention group
Intervention type: BEHAVIORAL
Intervention: Phone Interview/Questionnaire
Description: 35-minute questionnaire over the phone.
Study NCT03429309 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Anesthesia was induced by intravenous infusion of propofol via the syringe pump at a rate of 30 mg/kg/h.
Study NCT01702038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1000 mg administered intravenously
Study NCT00733460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFPET
Study NCT00607035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil ＋Azelnidipine
Description: The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
Study NCT00607035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil + Hydrochlorothiazide
Description: The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
Study NCT01133613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein 7
Description: Single intraarticular injection of BMP-7 or placebo on Day 1
Study NCT06250075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formulation with probiotics
Description: Lactobacillus acidophilus NCFM®, Lactobacillus paracasei Lpc-37 ™, Bifidobacterium lactis Bi-04™, Bifidobacterium lactis Bi-07™, Bifidobacterium bifidum Bb-02™)
Study NCT06250075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Formulation with probiotics
Description: Lactobacillus acidophilus NCFM®, Lactobacillus paracasei Lpc-37 ™, Bifidobacterium lactis Bi-04™, Bifidobacterium lactis Bi-07™, Bifidobacterium bifidum Bb-02™)
Study NCT00973271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid
Study NCT00973271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid
Study NCT03048240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: perPDT
Description: The protocol requires the realization of specific procedures in addition to the usual care.~The per-operative photodynamic therapy (perPDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery + lighting of the tumor bed by a light source (laser) at the end of resection (Prolonged surgery of 45 minutes).
Study NCT03048240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLIOLAN
Description: patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery
Study NCT03527446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training
Description: The 4-week sprint interval intervention will consist of a work-rest ratio of four 30-s intervals of exercise at maximal capacity and 4-min of passive recovery at 50% of maximal capacity between intervals. There will be three sessions per week.